Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Recurrent Malignant Glioma
NCT01740570Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2013
- Primary completion
- Apr 2017
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of cabazitaxel in malignant glioma, glioblastoma (GBM), Gliosarcoma (GS), sponsored by University of Texas MD Anderson Cancer Center. Planned start Apr 2013; status: withdrawn.
02
Drugs
cabazitaxel
03
Conditions
malignant gliomaglioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01740570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01740570.